Not applicable.
Funding
This study was supported through a Rising Stars Award, University of Texas System (SEW), UT MD Anderson Cancer Center NCI SPORE in Melanoma (SEW, P50 CA093459), NIH National Cancer Institute (NCI) grant T32 CA163185 (AES), NCI Grant No. U01 CA180964 (FMB), Khalifa Bin Zayed Al Nahyan Foundation, NCATS grant UL1 TR000371 (Center for Clinical and Translational Sciences), The University of Texas MD Anderson Cancer Center Support grant (NIH/NCI P30 CA016672), CPRIT RP150405 and Lung Cancer Moon Shot (DLG), Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Aim at Melanoma Foundation, Miriam & Jim Mulva Research Funds, and philanthropic contributions to The MD Anderson Cancer Center Melanoma Moon Shots Program.
Availability of data and materials
Data are available in the publications cited in the manuscript.
Authors’ contributions
Study concept and design: JR, SEW. Acquisition, analysis, or interpretation of data: JR, LH, KRH, JO, AJ, AES, TK, FS, VB, MT, JAW, KC, MF, CH, FM, AKE, KMS, and SEW. Preparation, review or approval of the manuscript: all authors.
Competing interests
Dr. Roszik is a consultant in Merck KGaA. Dr. Hess is an unpaid consultant in Angiochem, Inc. Dr. Tetzlaff serves on the advisory board for Advisory boards of Myriad Genetics and Seattle Genetics. Dr. Wargo is a speaker or advisory board for Dava Oncology, Roche Genentech, Novartis, GSK, and Illumina. Dr. Chen is an employee of Lion Biotechnologies. Dr. Meric-Bernstam has a consulting/advisory role in Genentech, Novartis, Roche, Inflection Biosciences, Celgene, and receives Honoraria from Genentech, Roche Diagnostics and research support from Novartis, AstraZeneca, Taiho Pharmaceutical, Genentech, Calithera Biosciences, Debiopharm Group, Bayer, Aileron Therapeutics, PUMA Biotechnology, Verastem, and CytomX Therapeutics. Dr. Mills is a consultant in Adventist Health, Allostery, AstraZeneca, Catena Pharmaceuticals, Critical Outcome Technologies, ImmunoMET, Isis Pharmaceuticals, Lilly, Medimmune, Novartis, Precision Medicine, Provista Diagnostics, Signalchem, Lifesciences, Symphogen, Takeda/Millenium Pharmaceuticals, Tau Therapeutics Tarveda, and receives sponsored research from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, AstraZeneca, Breast Cancer Research Foundation, Critical Outcome Technologies, Illumina, Karus, Komen Research Foundation, Nanostring, and Takeda/Millenium Pharmaceuticals. Dr. Gershenwald has a consulting or advisory role in Navidea, Castle Biosciences, and Merck, and intellectual property in Mercator therapeutics. Dr. Radvanyi is an employee of EMD Serono. Dr. Hwu has a stock or other ownership and consulting or advisory role in Lion Biotechnologies Immatics US, Inc., and receives research funding from Genentech and Bristol-Myers Squibb. Dr. Bernatchez has a consulting or advisory role in Lion Biotechnologies, and receives research funding from Nektar, Idera. Dr. Davies has a consulting or advisory role in GlaxoSmithKline, Genentech/Roche, Novartis, Sanofi, and Vaccinex, and receives research funding from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, GlaxoSmithKline, Genentech/Roche, AstraZeneca, Merck, Oncothyreon, Myriad Genetics, and Sanofi. No other disclosures are reported.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Samples for the ipilimumab treatment cohort were procured under MD Anderson protocols (PA11-0852 and 2004-0069). Samples for the ACT-TIL treatment cohort were procured under MD Anderson clinical protocol NCT00338377. These protocols were approved by the MD Anderson Cancer Center Institutional Review Board.